AbbVie to present new and updated data from 22 abstracts
Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study - Clinical Therapeutics
PDF) Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study
Frontiers | Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy | Neurology
Anti-Tau Drugs for PSP Move into Phase II - CurePSP
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares - ACR Meeting Abstracts
Clinical Study Protocol M15-563 An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Incorporating Administra
AbbVie to present new and updated data from 22 abstracts
1.0 Abstract
Summary of Clinical Trial Results
navocaftor (GLPG3067) - Larvol Sigma
Participation in an innovative patient support program reduces prescri | PPA
All Crohn's disease patient selection results. Abbreviations: CD,... | Download Scientific Diagram
PDF) Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis
AbbVie takes anti-tau drug into phase II for Alzheimer's - PMLiVE
Summary of Clinical Trial Results
Participation in an innovative patient support program reduces prescri | PPA
PDF) Higher Medication Adherence and Lower Opioid Use Among Individuals with Autoimmune Disease Enrolled in an Adalimumab Patient Support Program in the United States
AbbVie's Five Biggest Priorities, Apart From Allergan :: Scrip
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab – Author's reply
NCT03419403
AbbVie hoping for early data readout for anti-tau Alzheimer's drug | Fierce Biotech
